Data as of Apr 17
| +1.25 / +6.50%|
Chimerix, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of unmet medical need. Its proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens. Chimerix's lead product candidate, CMX001, is a broad spectrum antiviral against double-stranded DNA viruses. CMX157, is an oral nucleotide compound in Phase 1 development for the treatment of HIV infection. The company was founded in April 2000 and is headquartered in Durham, NC.
|M. Michelle Berrey||President, Chief Executive & Medical Officer|
|Timothy W. Trost||Chief Financial Officer, Secretary & Senior VP|
|Hervé Momméja-Marin||Vice President-Clinical Research|
|Linda M. Richardson||Chief Commercial Officer|
|Michael D. Rogers||Chief Development Officer|